A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
Key FDA decisions are expected to face delays.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A single-arm trial was enough for J&J’s Inlexzo nod.
